INS and polycystic ovary syndrome: A RCT on 100 non-overweight PCOS women (mean BMI of 24.6 kg/m2), administration of combined metformin (1.7 g/d) and rosiglitazone (4 mg/d) resulted in a significant reduction in WHR (-0.1%) and fasting glucose-to-insulin ratio compared with placebo group (0.0%) (28).